Fda accepts interim analysis plan for ongoing phase 2b ibezapolstat clinical trial and acurx announces presentations at eccmid 2023 scientific conference

Staten island, n.y. , april 11, 2023 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the fda has accepted the company's plan to have an independent data monitoring committee (idmc) conduct an interim review of clinical outcome from the ongoing ph2b clinical trial of patients with c.
ACXP Ratings Summary
ACXP Quant Ranking